Circulating secretory component-containing anti-citrullinated protein antibodies prior to symptom onset in rheumatoid arthritis
Authors' conclusion
Circulating SC ACPA responses arise and magnify during the asymptomatic phase of disease development in a subgroup of RA patients.
Study context
- Population
- Pre-symptomatic individuals subsequently developing rheumatoid arthritis (RA), with biobank controls
- Participants
- 319 / 181 / 100
- Comparison
- Pre-symptomatic individuals and RA patients vs controls
- Pre-symptomaticn = 319
- RAn = 181
- Controlsn = 100reference
- Outcome
- Circulating SC ACPA levels in plasma (enzyme-linked immunoassay)
Methodological detailsbiobank cohorts, randomly selected controls
- Biobank cohorts
- Randomly selected controls
Main finding
As reported in the abstract
Circulating SC ACPA levels
Pre-symptomatic vs Controls: P < 0.001 · RA vs Controls: P < 0.001 · RA vs Pre-symptomatic: P < 0.001
Observational data: associations, not effects.
Further findings
Total secretory IgA (TSIgA)
- Not elevated vs controls either during pre-dating time or after diagnosis
Earliest detected positive sample before symptom onset
- SC ACPA (years)
- 9
- IgG ACPA (years)
- 11
Pre-dating samples SC ACPA positive and IgG ACPA negative
- Samples
- 2
Original publication
Circulating secretory component-containing anti-citrullinated protein antibodies prior to symptom onset in rheumatoid arthritis. Rheumatology (Oxford). Published 21 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →